Corbus Pharmaceuticals (NASDAQ:CRBP) Now Covered by William Blair

Research analysts at William Blair started coverage on shares of Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report) in a report released on Friday, Marketbeat.com reports. The firm set an "outperform" rating on the biopharmaceutical company's stock.

Other research analysts also recently issued reports about the company. Piper Sandler started coverage on Corbus Pharmaceuticals in a research note on Monday, December 2nd. They set an "overweight" rating and a $35.00 price objective for the company. StockNews.com upgraded Corbus Pharmaceuticals to a "sell" rating in a research note on Monday, January 13th. HC Wainwright restated a "buy" rating and set a $75.00 price objective on shares of Corbus Pharmaceuticals in a research note on Tuesday, February 18th. Finally, Wedbush restated an "outperform" rating and set a $51.00 price objective on shares of Corbus Pharmaceuticals in a research note on Monday, November 4th. One analyst has rated the stock with a sell rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Corbus Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus target price of $61.38.

Corbus Pharmaceuticals Price Performance

Shares of CRBP stock traded down $0.59 on Friday, hitting $6.96. 241,771 shares of the stock traded hands, compared to its average volume of 251,180. The company has a market capitalization of $84.77 million, a PE ratio of -1.48 and a beta of 2.63. Corbus Pharmaceuticals has a 1-year low of $6.78 and a 1-year high of $61.90. The company's fifty day moving average is $10.47 and its 200 day moving average is $21.71.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of CRBP. Charles Schwab Investment Management Inc. boosted its stake in Corbus Pharmaceuticals by 224.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 93,643 shares of the biopharmaceutical company's stock valued at $1,932,000 after buying an additional 64,800 shares in the last quarter. State Street Corp boosted its stake in Corbus Pharmaceuticals by 34.6% during the third quarter. State Street Corp now owns 595,576 shares of the biopharmaceutical company's stock valued at $12,287,000 after buying an additional 153,243 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in Corbus Pharmaceuticals by 27.0% during the third quarter. JPMorgan Chase & Co. now owns 5,507 shares of the biopharmaceutical company's stock valued at $114,000 after buying an additional 1,172 shares in the last quarter. Geode Capital Management LLC boosted its stake in Corbus Pharmaceuticals by 8.1% during the third quarter. Geode Capital Management LLC now owns 249,759 shares of the biopharmaceutical company's stock valued at $5,154,000 after buying an additional 18,702 shares in the last quarter. Finally, HighVista Strategies LLC boosted its stake in Corbus Pharmaceuticals by 94.1% during the third quarter. HighVista Strategies LLC now owns 75,292 shares of the biopharmaceutical company's stock valued at $1,553,000 after buying an additional 36,499 shares in the last quarter. Institutional investors own 64.64% of the company's stock.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.